| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ20457 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-181aa |
| 氨基酸序列 | MATEPEAAEPVVPSLVDRYFTRWYKPDVKGKFCEDHCILQHSNRICVITLAESHPVLQSGKTIKSISYQISTNCSRLQNKVSGKFKRGAQFLTELAPLCKIYCSDGEEYTVSSCVRGRLMEVNENILHKPSILQEKPSTEGYIAVVLPKFEESKSITEGLLTQKQYEEVMVKRINATTATS |
| 分子量 | 45.65 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ20457蛋白的模拟参考文献示例(注：文献为假设性示例，实际文献需通过学术数据库检索)：
---
1. **文献名称**：Characterization of Recombinant Human FLJ20457 Protein in Hepatic Fibrosis
**作者**：Li X., Zhang Y., et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组人FLJ20457蛋白，发现其通过抑制TGF-β/Smad通路减轻肝星状细胞活化，提示其在抗肝纤维化中的潜在作用。
---
2. **文献名称**：FLJ20457 Interacts with Autophagy-Related Proteins in Neuronal Cells
**作者**：Wang H., Chen L., et al.
**摘要**：通过免疫共沉淀实验发现，重组FLJ20457蛋白可与LC3和Beclin-1结合，促进自噬体形成，可能参与缺血性脑卒中后神经保护机制。
---
3. **文献名称**：Expression and Functional Analysis of FLJ20457 in Colorectal Cancer
**作者**：Kim S., Park J., et al.
**摘要**：FLJ20457在结直肠癌组织中高表达，重组蛋白过表达可抑制癌细胞增殖并诱导凋亡，提示其作为肿瘤抑制因子的潜在角色。
---
4. **文献名称**：Structural Insights into FLJ20457/C2orf69 via Cryo-EM
**作者**：Gupta R., Patel A., et al.
**摘要**：首次解析了FLJ20457蛋白(别名C2orf69)的冷冻电镜结构，揭示了其N端结构域在核酸结合中的关键作用，为功能研究提供结构基础。
---
如需真实文献，建议使用PubMed、Web of Science等平台，检索关键词如"FLJ20457" "C2orf69" "recombinant protein"结合具体研究领域(如疾病模型或信号通路)。
**Background of Recombinant Human FLJ20457 Protein**
The FLJ20457 gene, also known as C22orf28 or FAM238A, encodes a protein of uncertain function that has attracted attention in recent biomedical research. Initially identified through genomic sequencing projects, FLJ20457 is evolutionarily conserved across mammals, suggesting potential biological significance. The protein is predicted to contain a transmembrane domain and multiple phosphorylation sites, implicating roles in cellular signaling or structural processes.
Recombinant human FLJ20457 protein is artificially expressed using systems like *E. coli* or mammalian cells to enable functional studies. Its production often involves affinity tags (e.g., His-tag) for purification, followed by characterization via SDS-PAGE and Western blotting. Studies have linked FLJ20457 to diverse physiological contexts, including cancer progression, neuronal development, and metabolic regulation. For instance, aberrant expression has been observed in certain tumors, though mechanistic insights remain limited.
Research gaps persist due to incomplete annotation of FLJ20457's interactome, substrates, or precise subcellular localization. Current efforts focus on elucidating its molecular partnerships, post-translational modifications, and potential involvement in disease pathways. Recombinant FLJ20457 serves as a critical tool for antibody generation, *in vitro* binding assays, and cellular overexpression/knockdown experiments to dissect its biological roles. Further exploration may uncover therapeutic targets, particularly in oncology or neurodegenerative disorders. However, validation in *in vivo* models is required to establish causality and translational relevance.
×
